Skip to main
TNGX

Tango Therapeutics (TNGX) Stock Forecast & Price Target

Tango Therapeutics (TNGX) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 55%
Buy 36%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

Tango Therapeutics is making significant progress in their development of PRMT5 inhibitors, with upcoming catalysts and positive data updates expected in the second half of 2026. Their partnerships with Revolution Medicines and Erasca provide a strong competitive advantage in the crowded KRAS inhibitor market and a clear path to market for their lead candidate vopimetostat. While there is competition in the PRMT5 space, Tango's differentiated safety profile makes them well-positioned for success. The potential for a partnership or acquisition by Revolution Medicines adds further upside to the stock. However, investors should also be aware of dilutive financing options and potential risks associated with debt offerings that may arise as the company continues to fund its operations.

Bears say

Tango Therapeutics is a promising biotechnology company focused on developing precision oncology therapies for the treatment of cancer, specifically non-CNS and CNS cancers. However, their success is largely dependent on the success of their lead asset, TNG462, and potential competition from other PRMT5 inhibitors, such as Bristol Myers' navlimetostat and Amgen's anvumetostat. Additionally, delays in advancing pipeline candidates, failure to achieve favorable clinical results, and potential FDA delays or issues could pose further risks to achieving their market value and price target. Furthermore, the competitive nature of the oncology market and emerging drugs targeting new mechanisms could also impact their potential for revenue and growth. Ultimately, the current outlook for Tango Therapeutics' stock is negative due to these potential risks and uncertainties.

Tango Therapeutics (TNGX) has been analyzed by 11 analysts, with a consensus rating of Buy. 55% of analysts recommend a Strong Buy, 36% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tango Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tango Therapeutics (TNGX) Forecast

Analysts have given Tango Therapeutics (TNGX) a Buy based on their latest research and market trends.

According to 11 analysts, Tango Therapeutics (TNGX) has a Buy consensus rating as of Aug 24, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tango Therapeutics (TNGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.